col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


69 Results       Page 1

 [1] 
BMJ: Journal for ImmunoTherapy of Cancer
  original article Date Title Authors   All Authors
1 [GO] 2023―Apr―28 Correction: JAK inhibitors and COVID-19
2 [GO] 2023―Feb―06 COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis Juan Ignacio Ruiz, Maria Angeles Lopez-Olivo, Yimin Geng, Maria E Suarez-Almazor
3 [GO] 2023―Jan―27 SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report Kevin Owen McNerney, Rebecca M Richards, Paibel Aguayo-Hiraldo, Friso G Calkoen, Julie-An Talano, Amy Moskop, et al. (+9)
4 [GO] 2022―Nov―30 Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries Alessio Cortellini, Gino M Dettorre, Urania Dafni, Juan Aguilar-Company, Luis Castelo-Branco, Matteo Lambertini, et al. (+37)
5 [GO] 2022―Nov―08 Correction: On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
6 [GO] 2022―Jul―18 T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine Djordje Atanackovic, Robert J Kreitman, Jeffrey Cohen, Nancy M Hardy, Destiny Omili, Thierry Iraguha, et al. (+7)
7 [GO] 2022―Jun―22 Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies Sherin Juliet Rouhani, Jovian Yu, Daniel Olson, Yuanyuan Zha, Apameh Pezeshk, Alexandra Cabanov, et al. (+8)
8 [GO] 2022―Apr―28 JAK inhibitors and COVID-19 Gabriel Levy, Paola Guglielmelli, Peter Langmuir, Stefan Constantinescu
9 [GO] 2022―Mar―10 Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
10 [GO] 2022―Mar―09 Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study Qi Mei, Guangyuan Hu, Yang Yang, Bo Liu, Junping Yin, Ming Li, et al. (+7)
11 [GO] 2022―Mar―03 Spontaneous tumor regression following COVID-19 vaccination Luana Guimaraes de Sousa, Daniel J McGrail, Kaiyi Li, Mario L Marques-Piubelli, Cipriano Gonzalez, Hui Dai, et al. (+6)
12 [GO] 2021―Nov―29 Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis Yifei Ma, Nianqi Liu, Youlong Wang, Jiling Zeng, Ying-Ying Hu, Wu Hao, et al. (+5)
13 [GO] 2021―Nov―09 701 Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC) Jason Luke, Jaime Merchan, Brett Hughes, Jeffrey Sosman, Abhishek Tripathi, Igor Puzanov, et al. (+9)
14 [GO] 2021―Nov―09 626 Dissecting the spatial heterogeneity of SARS-CoV-2-infected tumour microenvironment reveals a lymphocyte-dominant immune response in a HBV-associated HCC patient with COVID-19 history Benedict Tan, Yi Yang, Chun Chau Lawrence Cheung, Denise Goh, Mai Chan Lau, Xinru Lim, et al. (+12)
15 [GO] 2021―Nov―09 625 COVID-19 vaccination in patients with renal cancer or melanoma receiving immune checkpoint inhibitors Joyce Hwang, Hannah Dzimitrowicz, Riddhishkumar Shah, Kathleen Ashcraft, Daniel George, April Salama, Tian Zhang
16 [GO] 2021―Nov―09 896 Fighting the war against COVID-19: administration of bamlanivimab (BAM) or bamlanivimab + etesivimab (BAM + E); a cooperative effort between a community cancer center and an urgent care (UC) facility Patrick Skeffington, Robert Aisenberg, Janice Dallacosta, Ian Donaghy, Dani Hackner, Kelly Houde, et al. (+2)
17 [GO] 2021―Oct―13 Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
18 [GO] 2021―Oct―13 Correction: SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
19 [GO] 2021―Aug―05 Correction: COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report
20 [GO] 2021―Jul―16 Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors Benjamin Switzer, John Haanen, Paul C Lorigan, Igor Puzanov, Samra Turajlic
21 [GO] 2021―Jun―16 Correction: Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score
22 [GO] 2021―Jun―11 COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies Jason D Goldman, Philip C Robinson, Thomas S Uldrick, Per Ljungman
23 [GO] 2021―Jun―11 Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients Emanuela Romano, Steve Pascolo, Patrick Ott
24 [GO] 2021―May―13 Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy Lorenzo Iovino, Laurel A Thur, Sacha Gnjatic, Aude Chapuis, Filippo Milano, Joshua A Hill
25 [GO] 2021―May―07 Immune profiling of COVID-19: preliminary findings and implications for the pandemic Holden T Maecker
26 [GO] 2021―Apr―30 Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations Muhammad Bilal Abid
27 [GO] 2021―Apr―09 IL-6 modulation for COVID-19: the right patients at the right time? Paolo Antonio Ascierto, Binqing Fu, Haiming Wei
28 [GO] 2021―Mar―22 Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score Gino M Dettorre, Saoirse Dolly, Angela Loizidou, John Chester, Amanda Jackson, Uma Mukherjee, et al. (+55)
29 [GO] 2021―Mar―18 Severity of COVID-19 in patients with lung cancer: evidence and challenges Antonio Passaro, Christine Bestvina, Maria Velez Velez, Marina Chiara Garassino, Edward Garon, Solange Peters
30 [GO] 2021―Mar―11 Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic Renee N Donahue, Jennifer L Marté, Meghali Goswami, Nicole J Toney, Yo-Ting Tsai, James L Gulley, Jeffrey Schlom
31 [GO] 2021―Mar―09 Perspectives on COVID-19 and cancer immunotherapy: a review series Jason D Goldman, Paolo Antonio Ascierto
32 [GO] 2021―Feb―17 SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study Mario Mandala, Paul Lorigan, Matilde De Luca, Andrea Bianchetti, Barbara Merelli, Anna Cecilia Bettini, et al. (+8)
33 [GO] 2021―Feb―11 COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report Angelo Dipasquale, Pasquale Persico, Elena Lorenzi, Daoud Rahal, Armando Santoro, Matteo Simonelli
34 [GO] 2021―Jan―19 Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition Aljosja Rogiers, Ines Pires da Silva, Chiara Tentori, Carlo Alberto Tondini, Joseph M Grimes, Megan H Trager, et al. (+43)
35 [GO] 2020―Dec―10 Management of immune checkpoint therapy for patients with cancer in the face of COVID-19 Chen Shen, Qianru Li, Yongchang Wei, Yuting Li, Jun Li, Juan Tao
36 [GO] 2020―Nov―20 Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management Jennifer L Marté, Nicole J Toney, Lisa Cordes, Jeffrey Schlom, Renee N Donahue, James L Gulley
37 [GO] 2020―Nov―09 476 AK119, a humanized anti-CD73 monoclonal antibody, as Immunotherapy for COVID-19 Tingting Zhong, Zhaoliang Huang, Xinghua Pang, Na Chen, Konyew Kwek, Chris Wynne, et al. (+6)
38 [GO] 2020―Nov―09 659 Blocking cytokine IL-1 with anakinra for the prevention of cytokine release syndrome in COVID-19 Erik Soule, Jason Williams, Matthias Piesche
39 [GO] 2020―Nov―09 482 COVID-19 in patients with lung cancer receiving immunotherapy. A report from an spanish academic center David Viñal, Laura Gutierrez, Julia Villamayor, Oliver Higuera, Dario Sanchez Cabrero, Javier De Castro
40 [GO] 2020―Nov―09 826 Risk of COVID-19 infection among patients receiving immune checkpoint inhibitor therapy: a tertiary care hospital system collaboration with the Massachusetts department of health William Murphy, Vartan Pahalyants, Nikolai Klebanov, Nicholas Theodosakis, Leyre Zubiri, Monina Klevens, et al. (+3)
41 [GO] 2020―Nov―09 483 Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis Olivier Demaria, Julien Carvelli, Nassima Chouaki Benmansour, Joanna Fares, Luciana Batista, Marie-Laure Thibult, et al. (+11)
42 [GO] 2020―Nov―09 481 Impact of COVID-19 on Cancer Patients Receiving Immune Checkpoint Inhibitors Kevin Tyan, Ai-Tram Bui, Anita Giobbie-Hurder, Isaac Klein, Michael Manos, Leyre Zubiri, et al. (+6)
43 [GO] 2020―Nov―09 475 Incidental finding of colorectal cancer in a COVID-19 patient, followed by deep profiling of SARS-CoV-2-associated immune landscape and tumour microenvironment Chun Chau Lawrence Cheung, Xinru Lim, Denise Goh, Tracy Zhijun Tien, Jeffrey Chun Tatt Lim, Thuan Tong Tan, et al. (+5)
44 [GO] 2020―Nov―09 825 Deep immune profiling of SARS-CoV-2 associated immune microenvironment in cancer tissues from recovered COVID-19 patients Denise Goh, Chun Chau Lawrence Cheung, Xinru Lim, Tracy Zhijun Tien, Jeffrey Chun Tatt Lim, Sanjna Nilesh Nerurkar, et al. (+11)
45 [GO] 2020―Nov―09 477 Deep learning to drive COVID-19 rapid drug repurposing Sarah Kolitz, Jason Kim, Jenny Zhang, Yoonjeong Cha, Sailaja Battula, Rebecca Kusko, et al. (+3)
46 [GO] 2020―Nov―09 325 Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells Gerard Criner, Mehrdad Mobasher, Craig Hill, Shenshen Hu, Suresh Mahabhashyam, Joshua Brody, et al. (+3)
47 [GO] 2020―Nov―09 480 Preliminary evaluation of a novel coronavirus vaccine (CORVax) using electroporation of plasmid DNA encoding a stabilized prefusion SARS-CoV-2 spike protein alone or with transfection of plasmid IL-12 Shawn Jensen, Christopher Twitty, Christopher Paustian, Madelein Laws, Glenna McDonnell, Keith Wegmann, et al. (+17)
48 [GO] 2020―Nov―09 479 A lymph-node targeted amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2 Martin Steinbuck, Peter DeMuth, Lochana Seenappa, Christopher Haqq, Aniela Jakubowski, Lisa McNeil
49 [GO] 2020―Nov―09 326 SARS-CoV-2 specific T-cells in TIL from patients with epithelial cancer Pedro Noronha, Georgia Paraschoudi, Eric Sousa, Jéssica Kamiki, Patrícia António, Carolina Condenço, et al. (+8)
50 [GO] 2020―Nov―09 478 Translation of a therapeutic neoantigen vaccine workflow to SARS-CoV-2 vaccine development Christof Smith, Sarah Entwistle, Caryn Willis, Steven Vensko, Wolfgang Beck, Jason Garness, et al. (+19)
51 [GO] 2020―Nov―09 863 Identification and characterization of an immunodominant SARS-CoV-2-specific CD8 T cell response Anastasia Gangaev, Pia Kvistborg
52 [GO] 2020―Oct―16 Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey Nilasha Ghosh, Aidan Tirpack, Karmela K Chan, Anne R Bass
53 [GO] 2020―Oct―15 Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists Margaret Ottaviano, Marcello Curvietto, Pasquale Rescigno, Marianna Tortora, Giovannella Palmieri, Diana Giannarelli, et al. (+89)
54 [GO] 2020―Sep―07 A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study Chao Liu, Li Li, Kehan Song, Zhi-Ying Zhan, Yi Yao, Hongyun Gong, et al. (+7)
55 [GO] 2020―Sep―07 Correction: Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
56 [GO] 2020―Aug―26 Amendment to 'Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19'
57 [GO] 2020―Aug―11 Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy Vincenzo Montesarchio, Roberto Parella, Chiara Iommelli, Antonella Bianco, Elio Manzillo, Fiorentino Fraganza, et al. (+15)
58 [GO] 2020―Jul―30 SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity Jia Wei, Jianping Zhao, Meifang Han, Fankai Meng, Jianfeng Zhou
59 [GO] 2020―Jul―22 Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment Ernesto Rossi, Giovanni Schinzari, Giampaolo Tortora
60 [GO] 2020―Jul―16 ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19 Riyue Bao, Kyle Hernandez, Lei Huang, Jason John Luke
61 [GO] 2020―Jul―07 BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy Madhuri Koti, Alvaro Morales, Charles H Graham, David Robert Siemens
62 [GO] 2020―Jul―02 On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19 Thilo Gambichler, Judith Reuther, Christina H Scheel, Jürgen Christian Becker
63 [GO] 2020―Jun―18 Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management Jarushka Naidoo, Joshua E Reuss, Karthik Suresh, David Feller-Kopman, Patrick M Forde, Seema Mehta Steinke, et al. (+4)
64 [GO] 2020―May―20 COVID-19 and immune checkpoint inhibitors: initial considerations Ryan J Sullivan, Douglas B Johnson, Brian I Rini, Tomas G Neilan, Christine M Lovly, Javid J Moslehi, Kerry L Reynolds
65 [GO] 2020―May―20 COVID-19 and lung cancer: risks, mechanisms and treatment interactions Alfredo Addeo, Michel Obeid, Alex Friedlaender
66 [GO] 2020―May―20 Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy Michael T Serzan, Princy N Kumar, Michael B Atkins
67 [GO] 2020―May―08 The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response Fernanda I Arnaldez, Steven J O'Day, Charles G Drake, Bernard A Fox, Bingqing Fu, Walter J Urba, et al. (+5)
68 [GO] 2020―Apr―28 Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
69 [GO] 2020―Apr―16 Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 Paolo Antonio Ascierto, Bernard Fox, Walter Urba, Ana Carrizosa Anderson, Michael B Atkins, Ernest C Borden, et al. (+28)
 [1] 

69 Results       Page 1


[de][en]

Last change 2023―Apr―13 19:50:14 UTC

© Daten-Quadrat 2022       Done in 0.018 sec